Search

In a study comparing two types of drug-eluting stents, three patients developed serious complications while being treated with sirolimus. Patient 1 experienced a stroke, Patient 2 had a myocardial infarction (heart attack), and Patient 3 developed stent thrombosis. The patients received different types of stents, but all were second-generation bioabsorbable polymer sirolimus-eluting stents. These cases highlight potential risks associated with sirolimus treatment, although specific details about the patients' ages, sexes, dosages, and treatment durations were not provided. [Extracted from the article]

A 68-year-old man with a history of myocardial infarction, hypertension, type 2 diabetes mellitus, and chronic kidney disease experienced lack of efficacy during treatment with furosemide for acute decompensated heart failure and severe acute kidney injury. Despite receiving increasing doses of furosemide, the patient did not respond and developed severe oliguria. His serum creatinine levels also increased. The man ultimately underwent continuous renal replacement therapy, which was discontinued after 36 hours when his urine output increased and his serum creatinine levels declined. [Extracted from the article]

A retrospective study published in the European Journal of Clinical Pharmacology found that short-term use of proton pump inhibitors (PPIs) in intensive care unit (ICU) patients with myocardial infarction (MI) increases the risk of rehospitalization for MI. The study analyzed data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database from 2008 to 2019 and compared the risks of rehospitalization for MI and heart failure in patients who received PPIs versus those who did not. The analysis showed that PPI use significantly increased the 1-year incidence rate of rehospitalization for MI, particularly in patients who received pantoprazole. However, PPI use did not significantly increase the risk of rehospitalization for heart failure. The authors concluded that omeprazole was relatively superior to pantoprazole in terms of the risks of rehospitalization in ICU-admitted MI patients. [Extracted from the article]

B. Braun Medical has issued a voluntary recall of two lots of 0.9% Sodium Chloride for Injection USP 1000 mL in E3 containers in the US due to the potential for particulate matter and fluid leakage. Although no customer complaints or reports of serious injury or death have been received, there is a risk of embolic events and infection if the particulates are not sterile. The affected batches, Lots J2L763 and J2L764, were distributed nationwide in the US in February 2024 and have an expiry date of March 31, 2025. B. Braun has notified distributors and customers and is arranging for the return of all recalled products. [Extracted from the article]

A 41-year-old man experienced an acute heart attack and chronic ischaemic heart disease as a result of abusing metamfetamine and amfetamine. He sought medical help for chest pain and was given diazepam and paracetamol to relieve the pain. Despite being discharged twice with normal findings, he was found dead the next morning. Autopsy results indicated that he died from an acute heart attack and chronic ischaemic heart disease caused by the abuse of metamfetamine and amfetamine. [Extracted from the article]

This article presents a case series involving 11 patients with Evans syndrome (ES), a rare autoimmune disorder. The focus is on five patients, aged between 35-67 years, who experienced various toxicities while being treated with different drugs for ES. These toxicities included deep venous thrombosis, bone marrow fibrosis, acute myocardial infarction, cerebral vein thrombosis, and splancnic thrombosis. The drugs involved in the cases were romiplostim, eltrombopag, rituximab, immune-globulin, and unspecified steroids. The article provides details of each case, including the treatments received and the outcomes. [Extracted from the article]

Two case reports are presented in this article, highlighting the lack of efficacy of various drugs in the treatment of Kawasaki's disease and aneurysms. In the first case, a 3-month-old boy received multiple treatments including infliximab, aspirin, heparin, immune-globulin, and steroids, but still experienced thrombus persistence. Clopidogrel and cyclosporin were then administered, resulting in the resolution of aneurysms. The second case involved a 10-month-old girl who received immune-globulin, heparin, alteplase, and steroids, but unfortunately died from myocardial infarction. These cases emphasize the need for further research and alternative treatment options for these conditions. [Extracted from the article]

Two case reports describe men aged 49-50 who experienced a lack of efficacy with various medications for neuropathic pain. The first patient, a 49-year-old man with a history of spinal cord injury, tried amitriptyline, gabapentin, and pregabalin without success. He found temporary relief with hydrocodone/paracetamol. The second patient, a 50-year-old man with multiple health conditions, tried gabapentin, pregabalin, baclofen, and oxycodone/paracetamol without improvement. Both patients eventually underwent spinal cord stimulation trials, which provided significant pain relief. [Extracted from the article]

A 57-year-old woman experienced hyperglycemia and dyslipidemia while being treated for breast cancer with dexamethasone and antipsychotic therapy with olanzapine. Her medical history included a recent breast cancer diagnosis and she was taking multiple medications concurrently. The combination of olanzapine and dexamethasone was determined to be the cause of her hyperglycemia and dyslipidemia. The woman was counseled on lifestyle modifications and started on medication to manage her symptoms. Her lipid levels improved after treatment adjustments. [Extracted from the article]

A 59-year-old man experienced nausea while being treated with cinacalcet for hypercalcaemia. He also showed a lack of efficacy with denosumab while being treated for parathyroid carcinoma. The man initially had hypercalcaemia due to parathyroid adenoma and underwent parathyroidectomy, which resolved the hypercalcaemia. However, it recurred and he started taking cinacalcet, which caused nausea. He also developed hypertension and chronic kidney disease, requiring haemodialysis. Eventually, he suffered a myocardial infarction and died, indicating a lack of efficacy in his treatment. [Extracted from the article]

A 59-year-old man with a history of myocardial infarction, decompensated heart failure, and hypertension experienced a lack of efficacy during treatment with warfarin for a left ventricular thrombus. He developed symptoms such as fatigue, edema, and decreased urinary output, leading to hospitalization for decompensated heart failure. Despite being on warfarin, he later developed right hemiplegia, dysarthria, and worsening consciousness, and intracardiac thrombi were detected. This case highlights a lack of efficacy of warfarin in this particular patient. [Extracted from the article]

A 74-year-old man developed severe thrombocytopenia while receiving prophylaxis with tirofiban for platelet aggregation and thrombus formation. The man presented with chest pain and was diagnosed with a non-ST-segment elevation myocardial infarction. He received various medications, including tirofiban, and experienced nausea, abdominal pain, and chills shortly after tirofiban initiation. The man was diagnosed with tirofiban-induced severe thrombocytopenia and received treatment, including platelet transfusion. His condition improved, and he was discharged from the hospital after five days. [Extracted from the article]

A 42-year-old man with antiphospholipid syndrome and a history of thrombosis and myocardial infarctions exhibited lack of efficacy during treatment with rivaroxaban, aspirin, hydroxychloroquine, and warfarin. Despite receiving these medications, he experienced recurrent episodes of thrombosis and two myocardial infarctions. A cava filter was implanted, and he underwent coronary artery thrombus aspiration and stenting. However, he was resistant to warfarin, and his rivaroxaban was replaced with an unspecified low molecular weight heparin. [Extracted from the article]

A retrospective study described 11 patients, aged 9-74 years, who developed DRESS syndrome while being treated with various drugs including allopurinol, carbamazepine, leflunomide, sodium-valproate, and sulfasalazine. The patients experienced symptoms of DRESS syndrome 2-8 weeks after starting treatment. Laboratory tests showed abnormal leukocyte counts, eosinophil counts, AST, and ALT levels. Treatment with prednisolone or ciclosporin resulted in improvement, but unfortunately, two patients later died from sepsis-nosocomial infection or myocardial infarction and heart failure. [Extracted from the article]

A 36-year-old man experienced an acute myocardial infarction (MI) while being treated with methadone for opioid use disorder. The man had a history of diabetes and was a smoker. He had symptoms such as shortness of breath, chest pain, dizziness, palpitations, syncope, and signs suggesting a cardiac cause. An EKG showed ST elevation and Q waves indicative of an MI, and a coronary angiogram revealed lesions in his right coronary artery. The man underwent coronary angiography with percutaneous intervention and recovered. [Extracted from the article]

A 37-year-old woman experienced Kounis syndrome, a condition characterized by an allergic reaction leading to acute myocardial infarction, while receiving anti-inflammatory treatment with hydrocortisone. She developed thoracic pain, hypotension, and diaphoresis immediately after receiving the hydrocortisone. Further investigations confirmed the diagnosis of Kounis syndrome, and the woman was treated with fluid therapy and morphine, resulting in the resolution of her symptoms and a return to normal blood pressure. The Kounis syndrome completely resolved during her hospital stay. [Extracted from the article]

This article discusses three case reports of patients who experienced adverse effects or lack of efficacy during treatment with atezolizumab and bevacizumab for hepatocellular carcinoma (HCC). The first case involved a 79-year-old man with chronic kidney disease who developed hypothyroidism and eventually died. The second case involved a 75-year-old woman who experienced a pathological fracture and metastasis, leading to discontinuation of the therapy. The third case involved an 81-year-old man who had increased tumor markers and tumor enlargement, resulting in discontinuation of the therapy. These case reports highlight potential complications and lack of effectiveness associated with this treatment for HCC. [Extracted from the article]

Long-term treatment with oral corticosteroids for over 90 days in patients with atopic dermatitis (AD) may increase the risk of adverse events (AEs), according to a study published in JAMA Network Open. The study analyzed data from the Health Insurance Review and Assessment Service database of South Korea and found that the use of oral corticosteroids for over 90 days slightly increased the risk of AEs such as fracture, hyperlipidemia, myocardial infarction, and avascular necrosis. The authors suggest that limiting the duration of oral corticosteroid treatment to 90 days or less may help reduce adverse effects in patients with AD. [Extracted from the article]

A 33-year-old man experienced acute myocardial infarction after abusing testosterone. The man, who was a bodybuilder, had a history of pulmonary embolism and reported using testosterone 250-300mg weekly. He presented with sudden chest pain and was treated with heparin and anti-platelet therapy. Coronary arteriography showed a thrombotic occlusion, and cardiac MRI confirmed the diagnosis of acute myocardial infarction. After discontinuing testosterone, the man's symptoms resolved, and he was discharged with follow-up care. [Extracted from the article]

A 61-year-old man experienced a myocardial infarction with non-obstructive coronary arteries (MINOCA) while being treated with olverembatinib for myeloproliferative neoplasm. The patient had a history of well-controlled hypertension and had quit smoking six months prior. He began experiencing chest discomfort and decreased exercise capacity, and a coronary angiography revealed mild stenotic lesions. However, his symptoms worsened, and he developed persistent chest pain. Further testing showed severe stenosis in the left main artery and normal right coronary artery, indicating coronary artery spasm. The patient underwent balloon angioplasty and his symptoms improved. The treatment with olverembatinib was stopped, and he was transferred for additional therapy. It was concluded that the MINOCA was induced by olverembatinib. [Extracted from the article]

A 79-year-old woman experienced rhabdomyolysis while being treated with rosuvastatin for acute myocardial infarction. She was hospitalized due to rhabdomyolysis and acute renal failure. The woman had previously undergone percutaneous coronary intervention and received rosuvastatin along with other medications. Genotyping revealed polymorphisms in genes involved in rosuvastatin metabolism and transport, which likely resulted in slower metabolism and the accumulation of rosuvastatin in her plasma. This led to the development of rhabdomyolysis and subsequent acute renal failure. [Extracted from the article]

In a study involving 18 patients, a case was described where a patient exhibited a lack of efficacy during treatment with aspirin and ticagrelor for acute myocardial infarction. The patient was diagnosed with acute myocardial infarction and started receiving treatment with aspirin and ticagrelor. However, the patient showed ineffective inhibition of platelets with these medications, indicating a lack of efficacy. The study highlights the need for further research and investigation into alternative treatment options for patients with similar conditions. [Extracted from the article]

A 75-year-old woman experienced a 2:1 atrioventricular (AV) block after using bortezomib plus dexamethasone (BDex) off-label for POEMS syndrome. The woman had a history of various medical conditions and underwent surgeries and treatments prior to starting BDex therapy. After 15 days of treatment, she developed bradycardia and was diagnosed with AV block. BDex therapy was stopped, and she received temporary and permanent pacemaker implantation. After resuming BDex therapy, her symptoms improved, and she continued the treatment for the next 9 years with good results. [Extracted from the article]

A 50-year-old man developed acute colitis while being treated with nicorandil for acute myocardial infarction. He experienced acute bloody diarrhea with mucous for three days after thrombolysis. Despite receiving antibiotics and antiamoebics, his symptoms persisted. A flexible sigmoidoscopy revealed ulcerations and active bleeding. Biopsies showed inflammation but no infection or malignancy. The patient's medication history indicated that he had received nicorandil infusion and tablets. Withholding nicorandil led to improvement in the colitis. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA man [exact age not stated] developed myocardial infarction with non-obstructive coronary arteries (MINOCA) following topical naphazoline abuse [dosage, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

A 77-year-old man experienced positive fecal occult blood and lack of efficacy while being treated with multiple drugs for coronary artery ectasia associated with IgG4-related disease. The man initially received dual antiplatelet treatment with prednisone and mycophenolate mofetil, which provided relief from chest pain and normalized his ESR and C-reactive protein levels. However, he experienced a recurrence of symptoms and an increase in fecal occult blood, which was attributed to aspirin. Despite subsequent treatment with aspirin, atorvastatin, clopidogrel, epinephrine, lidocaine, and prednisone, the man's condition continued to worsen, and he ultimately passed away. [Extracted from the article]

A retrospective study called TRAIT examined 267 patients with immune thrombocytopenia (ITP) who were treated with eltrombopag or romiplostim. Out of the 12 patients described in the study, various adverse reactions were observed, including peripheral edema, arthralgia, dehydration, eye disorder, myocardial infarction, platelet count increase, pulmonary embolism, visual disturbances, vomiting, renal failure, and lack of efficacy. Most of these patients were admitted to the hospital, and one patient died due to ITP. It is important for patients and healthcare providers to be aware of these potential toxicities associated with these treatments. [Extracted from the article]

An adult woman with A20 haploinsufficiency experienced drug ineffectiveness while being treated with colchicine. She had previously suffered from recurrent myocardial infarction and had undergone stenting intervention. Despite being prescribed colchicine, it was found to be ineffective in treating her condition. As a result, she was given adalimumab, which led to improvement. [Extracted from the article]

A man in his early 60s with a history of type 2 diabetes and hypertension experienced a lack of efficacy during treatment with aspirin, atorvastatin, clopidogrel, and sirolimus for severe coronary stenosis. After being admitted to the emergency room with chest pain and undergoing a coronary angiogram, a sirolimus stent was implanted. However, the man was readmitted the next day after being stung by bees and experienced chest tightness, nausea, and headache. He was diagnosed with acute myocardial infarction and underwent another angiogram, which revealed stent thrombosis. After treatment, he was discharged with the same medications and had no evidence of restenosis after a year. [Extracted from the article]

A 59-year-old man experienced lack of efficacy during treatment with heparin for thromboembolism prophylaxis in ventricular septal rupture (VSR) repair. After complaining of sudden chest pain, he was diagnosed with acute myocardial infarction (AMI) and underwent emergency percutaneous coronary intervention (PCI). Four days later, echocardiography revealed a left-to-right shunt with VSR, leading to the insertion of an Impella CP device. However, the patient developed pulmonary edema and required early surgery. Following surgery, heparin administration resumed but resulted in thromboembolism, which was treated with emergency thrombectomy. The patient recovered and was discharged home after rehabilitation. [Extracted from the article]

A 50-year-old man experienced thrombocytopenia while being treated with heparin for thrombosis prevention. He also showed a lack of effectiveness when treated with bivalirudin and cangrelor for the same purpose. The man had a medical history of obesity, obstructive sleep apnea, and tobacco use. After experiencing a cardiac arrest due to acute myocardial infarction, he underwent several medical procedures and was eventually diagnosed with heparin-induced thrombocytopenia. Treatment with bivalirudin and cangrelor was discontinued due to concerns of lack of efficacy, and the man was successfully decannulated from extracorporeal membrane oxygenation (ECMO) after receiving thrombolysis treatment. [Extracted from the article]

A 75-year-old man with oesophageal cancer developed pyothorax and constrictive pericarditis during treatment with anti-cancer drugs. He also experienced lack of efficacy during treatment with urokinase for acute myocardial infarction. The man had a history of hyperuricaemia and heavy smoking. Despite undergoing chemoradiotherapy and various treatments, his condition worsened, leading to his death. Autopsy results revealed pericardial thickening and fungal infections in the pericardium and myocardium. [Extracted from the article]

The US FDA has issued a warning to consumers about the use of Infla-650, a dietary supplement sold for pain relief. The supplement has been found to contain undeclared acetaminophen (paracetamol) and two nonsteroidal anti-inflammatory drugs (NSAIDs). The FDA has confirmed through laboratory analysis that Infla-650 contains paracetamol, diclofenac, and phenylbutazone, making it a potentially unsafe medication health fraud product. The use of Infla-650 poses serious risks, including unintentional paracetamol overdose, liver damage, cardiovascular events, gastrointestinal damage, and adverse interactions with other medicines. Healthcare professionals and consumers are advised to report any adverse events related to the use of Infla-650 to the FDA. [Extracted from the article]

In a retrospective study, two men were described who experienced serious adverse events while receiving treatment for different medical conditions. The first man, aged 63, developed cerebral hemorrhage while being treated for acute myocardial infarction with reteplase and metoprolol. Unfortunately, he died within 24 hours. The second man, aged 54, developed gastrointestinal bleeding while being treated for coronary atherosclerotic heart disease and bronchiectasis with aspirin, diclofenac sodium, and low-molecular heparin calcium. He also died as a result of the bleeding. These cases highlight the potential risks associated with these medications, but further research is needed to fully understand the relationship between the treatments and the adverse events. [Extracted from the article]

Two lots of Docetaxel Injection are being recalled in the US due to the potential presence of particulate matter. The recall was initiated by Sagent Pharmaceuticals following a customer complaint. The presence of particulate matter in an injectable product can lead to serious adverse events such as phlebitis, granuloma, and thrombosis. However, as of the publication date, no adverse events related to this recall have been reported. Consumers, distributors, and retailers are advised to stop using the recalled products and return them to Sagent. Any adverse reactions or quality problems can be reported to the FDA MedWatch Adverse Event Reporting program. [Extracted from the article]

An 85-year-old woman experienced a stroke and myocardial infarction while being treated with andexanet alfa to reverse the effects of apixaban. The woman had a history of atrial fibrillation and was taking apixaban. After receiving andexanet alfa in the ICU, she developed confusion and chest discomfort. Physical examination revealed left-sided hemineglect, and further tests showed elevated Troponin-T levels and ST elevation. MRI results indicated multiple acute embolic strokes. The woman ultimately passed away, but the cause of death was not specified. [Extracted from the article]

An 85-year-old woman experienced a stroke and myocardial infarction while being treated with andexanet alfa to reverse the effects of apixaban. The woman had a history of atrial fibrillation and was taking apixaban. After receiving andexanet alfa in the ICU, she developed confusion and chest discomfort. Further examination revealed left-sided hemineglect and elevated Troponin-T levels. MRI results showed multiple acute embolic strokes. The woman ultimately passed away, but the cause of death was not specified. [Extracted from the article]

The US FDA is warning consumers not to use the dietary supplement Ossos-Sans, as it has been found to contain unlisted ingredients, diclofenac and methocarbamol. These ingredients pose potential risks, such as cardiovascular events and gastrointestinal damage in the case of diclofenac, and sedation and impaired ability to operate machinery in the case of methocarbamol. The FDA is urging healthcare professionals and consumers to report any adverse events related to the use of this product. [Extracted from the article]

The US FDA has issued a warning about the dietary supplement Ossos-Sans, as it has been found to contain unlisted ingredients, diclofenac and methocarbamol. Diclofenac is a nonsteroidal anti-inflammatory drug that can increase the risk of cardiovascular events and cause gastrointestinal damage. Methocarbamol is a muscle relaxant that can cause sedation and impair driving ability. The FDA is urging healthcare professionals and consumers to report any adverse events related to the use of this product. [Extracted from the article]

A 40-year-old woman experienced coronary thrombosis and myocardial infarction after abusing methamphetamine. The woman had a history of polysubstance use and had previously been admitted for a non-ST-elevation myocardial infarction (NSTEMI) that resolved without intervention. During her current presentation, she experienced severe chest pain and cardiac arrest. She received resuscitation and underwent mechanical thrombectomy, with a drug-eluting stent inserted in her left anterior descending artery. Urine drug analysis confirmed the presence of amphetamines and benzodiazepines. The woman's decreased left ventricular ejection fraction (LVEF) indicated cardiomyopathy. The conclusion was that the coronary thrombosis was a result of methamphetamine abuse, leading to myocardial infarction and complications resulting in cardiac arrest. [Extracted from the article]

An 80-year-old man experienced a lack of efficacy during treatment with eptifibatide for cardioembolic myocardial infarction. The patient presented with acute chest pain and had a history of atrial fibrillation. Multiple clots were found in the patient's arteries, leading to the diagnosis of cardioembolic myocardial infarction. Treatment involved the use of a manual aspiration catheter and intra-coronary boluses of eptifibatide. After a second run with the catheter, blood flow was restored and the patient showed improvement. [Extracted from the article]

A 50-year-old man developed heparin-induced thrombocytopenia while being treated with heparin for acute myocardial infarction. He initially presented with severe chest pain and was diagnosed with acute myocardial infarction. He received aspirin, ticagrelor, and heparin, and underwent percutaneous coronary intervention. However, he experienced a sudden drop in blood pressure and ventricular fibrillation, leading to the suspicion of cardiogenic shock. Thrombi were found in his left ventricle, pulmonary arteries, and aortic arch, confirming the diagnosis of heparin-induced thrombocytopenia. Heparin was discontinued and replaced with apixaban, and the patient's condition improved with no further complications. [Extracted from the article]

A retrospective study involving 83 patients with polycythemia vera found that some patients developed various complications while being treated with ruxolitinib. These complications included splenic vein thrombosis, acute myocardial infarction, prostate cancer, bladder cancer, and laryngeal cancer. The study did not provide specific information about the ages, sexes, dosages, or durations of treatment for these patients. It is important for individuals considering ruxolitinib treatment to be aware of these potential risks. [Extracted from the article]

A 63-year-old man with cervical angina did not experience any improvement while being treated with diclofenac, pethidine, tramadol, meloxicam, morphine, and pregabalin. He initially presented with left upper limb pain that progressed to severe pain in the left shoulder, neck, and chest, accompanied by headache episodes. Despite receiving various medications and treatment for suspected ulcers and myocardial infarction, his pain did not improve. However, after being diagnosed with C7 cervical radiculopathy and starting prednisolone, his symptoms significantly improved the following day. [Extracted from the article]

A 73-year-old man experienced ventricular septal rupture while being treated with methylprednisolone for chronic obstructive pulmonary disease exacerbation. He presented with symptoms of a heart attack and was found to have severe coronary artery disease. After receiving methylprednisolone, he developed hypoxia and biventricular failure. Further tests confirmed the diagnosis of ventricular septal rupture caused by the medication. The outcome of the patient was not mentioned in the article. [Extracted from the article]

In a retrospective pharmacovigilance study, three patients were described who experienced various toxicities and pharmacokinetic drug interactions while being treated with pitolisant for narcolepsy. Two patients developed myocardial infarction, dizziness, or myocarditis, and one patient developed pulmonary embolism. Unfortunately, one patient died due to myocardial infarction. The patients were also receiving other medications, including venlafaxine, methylphenidate, pramipexole, mixed-amfetamine-salts, amfetamine, lisdexamfetamine, sodium-oxybate, escitalopram, desloratadine, fluvoxamine, aripiprazole, and diazepam. It was identified that a pharmacokinetic drug interaction between pitolisant, fluvoxamine, aripiprazole, and diazepam contributed to the development of pulmonary embolism in one patient. [Extracted from the article]

A 67-year-old woman developed vaccine-induced immune thrombotic thrombocytopenia (VITT) following the AZD-1222 vaccination. She experienced symptoms such as petechiae, ecchymosis, epistaxis, bleeding gums, and a frontal headache. The woman had a history of immune-thrombocytopenia purpura and had previously undergone splenectomy. She received treatment with immune-globulin and glucocorticoids, and her platelet count improved over time. The article provides a case study of VITT following the AZD-1222 vaccine and highlights the importance of monitoring and managing potential adverse effects. [Extracted from the article]

An 80-year-old woman experienced a serious adverse event while being treated with tranexamic acid for a suspected gastrointestinal bleed. The woman had no prior history of cardiac disease but developed ST-elevation myocardial infarction after starting treatment with tranexamic acid. Her electrocardiogram showed ST elevations in the inferior leads, and catheterization revealed a complete blockage of the proximal right coronary artery. The woman underwent aspiration thrombectomy and balloon angioplasty. [Extracted from the article]

A 54-year-old man experienced pulmonary hemorrhage while being treated with ticagrelor for a myocardial infarction. After undergoing a primary percutaneous coronary intervention, he was discharged and started taking ticagrelor as part of his post-myocardial infarction treatment. However, one day after discharge, he presented to the emergency department with dyspnea and hemoptysis. Imaging revealed diffuse pulmonary hemorrhage, but no malignancy or infectious causes were found. The medical team discontinued ticagrelor and switched to clopidogrel, resulting in the man's gradual improvement and complete resolution of symptoms by the fifth day of admission. [Extracted from the article]

A 66-year-old man experienced polycythemia (an increase in red blood cells) and a heart attack while undergoing testosterone treatment. The man had pre-existing conditions including hypertension, type 2 diabetes, and hyperlipidemia. He presented with chest pain and dizziness, and further tests revealed a blockage in one of his arteries. He underwent a procedure to open the artery and was diagnosed with polycythemia and a heart attack. The man was treated with hydroxycarbamide and received plasmapheresis for his polycythemia. [Extracted from the article]